logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Chiesi USA, Inc. drugs

    FiltersReset Filters
    15 results

    • bethkis - tobramycin solution

      (Tobramycin)
      Chiesi Usa, Inc.

    • cleviprex

      (clevipidine)
      Chiesi USA, Inc.
      Usage: Cleviprex is indicated for lowering blood pressure in situations where oral medication is not feasible or desirable.

    • curosurf

      (poractant alfa)
      Chiesi USA, Inc.
      Usage: CUROSURF® (poractant alfa) is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants, helping to reduce mortality and the occurrence of pneumothoraces associated with the condition.

    • elfabrio

      (pegunigalsidase alfa)
      Chiesi USA, Inc.
      Usage: ELFABRIO is indicated for the treatment of adults with confirmed Fabry disease.

    • ferriprox

      (deferiprone)
      Chiesi USA, Inc.
      Usage: FERRIPROX Tablets are indicated for treating transfusional iron overload in adults and pediatric patients (8 years and older) with thalassemia syndromes, sickle cell disease, or other anemias. Safety and effectiveness are not established for use in myelodysplastic syndrome or Diamond Blackfan anemia.

    • ferriprox - deferiprone solution

      (Deferiprone)
      Chiesi Usa, Inc.

    • ferriprox - deferiprone tablet

      (Deferiprone)
      Chiesi Usa, Inc.

    • filsuvez - birch triterpenes gel

      (Birch Triterpenes)
      Chiesi Usa, Inc.

    • juxtapid - lomitapide mesylate capsule

      (Lomitapide Mesylate)
      Chiesi Usa, Inc.

    • kengreal

      (cangrelor)
      Chiesi USA, Inc.
      Usage: KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to lower the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis in patients who have not received a P2Y12 platelet inhibitor and are not on a glycoprotein IIb/IIIa inhibitor.